Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform ...

Five-year forecasts by application, technology, product and setting, from clinical labs to point of care, as syndromic multiplex panels reshape molecular diagnostics after the pandemic.Dublin, Oct. 08 ...

A Colombian study of 478 patients found that routine cerebrospinal fluid white cell counts and protein levels could predict ...

EVANSTON, Ill.--(BUSINESS WIRE)--Minute Molecular Diagnostics today announced that the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its rapid DASH ...

VITALiS and Applied BioCode today announced an expanded collaboration to support the adoption and internalization of gastrointestinal (GI) pathogen testing in commercial and physician office ...

BERLIN, June 4, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it developed a Research Use Only (RUO) molecular PCR test, via its subsidiary TIB MOLBIOL, for use on the ...

cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, ...

The US Food and Drug Administration has cleared a new multiplex gastrointestinal PCR assay designed to streamline the detection of common diarrhea-causing pathogens from a single patient sample. The ...

How automation, decentralisation and indigenous manufacturing are redefining access to precision molecular testing explains, ...

Detailed price information for Co-Diagnostics Inc (CODX-Q) from The Globe and Mail including charting and trades.

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C. Co-Diagnostics and ReadyGo target decentralized Ebola detection as th ...

A new PCR-based study in Venezuela shows that msp5-targeting diagnostics outperform msp2 primers for detecting Anaplasma ...